Literature DB >> 8823296

Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma.

L Lavaissiere1, S Jia, M Nishiyama, S de la Monte, A M Stern, J R Wands, P A Friedman.   

Abstract

To characterize genes that become upregulated with malignant transformation of human hepatocytes, a library of monoclonal antibodies was produced against the FOCUS hepatocellular carcinoma cell line. Antibody FB-50 reacted with an antigen that was highly expressed in 4 of 10 primary hepatocellular carcinomas, in all 20 cholangiocarcinomas we studied, and in a variety of transformed cell lines. This antigen was also highly expressed in neoplastic epithelial cells of breast and colon carcinomas in contrast to its low level of expression in normal hepatocytes and in non-neoplastic epithelial cells. Among the normal adult tissues studied, high levels were observed only in proliferating trophoblastic cells of the placenta and in adrenal glands. A 636-bp partial cDNA, isolated from a gamma GT11 expression library generated with HepG2 human hepatoblastoma cells, and a complete cDNA, generated by reverse transcriptase-PCR, identified the antigen as the human form of aspartyl(asparaginyl)beta-hydroxylase. This enzyme catalyzes posttranslational hydroxylation of beta carbons of specific aspartyl and asparaginyl residues in EGF-like domains of certain proteins. Analyses of extracts prepared from several human tumor cell lines compared to their normal tissue counterparts indicate that the increase in hydroxylase, approximately 10-fold, is controlled at the level of transcription and the protein is expressed in an enzymatically active form. In similar analyses, comparing hepatocellular carcinomas to adjacent uninvolved liver from five patients, enzymatic activity was much higher in the tumor tissue from the four patients whose immunoblots revealed increased hydroxylase protein in the malignant tissue. EGF repeats in the extracellular domain of Notch or its homologs contain the consensus sequence for hydroxylation. Deletion mutants lacking this domain are gain-of-function mutants, suggesting that the domain modulates signal transduction by the cytoplasmic domain. While the function imparted by beta hydroxylation is unknown, our studies raise the possibility that beta hydroxylation is regulated in proteins like the mammalian Notch homologs, whose cytoplasmic domains have been shown to be oncogenic.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8823296      PMCID: PMC507557          DOI: 10.1172/JCI118918

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

Review 1.  Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors.

Authors:  J Stenflo
Journal:  Blood       Date:  1991-10-01       Impact factor: 22.113

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Fluorescence in situ hybridization with human chromosome-specific libraries: detection of trisomy 21 and translocations of chromosome 4.

Authors:  D Pinkel; J Landegent; C Collins; J Fuscoe; R Segraves; J Lucas; J Gray
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

4.  A comprehensive set of sequence analysis programs for the VAX.

Authors:  J Devereux; P Haeberli; O Smithies
Journal:  Nucleic Acids Res       Date:  1984-01-11       Impact factor: 16.971

5.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

6.  Human hepatoma-associated cell surface antigen: identification and characterization by means of monoclonal antibodies.

Authors:  D Shouval; D Eilat; R I Carlson; R Adler; N Livni; J R Wands
Journal:  Hepatology       Date:  1985 May-Jun       Impact factor: 17.425

7.  Establishment and characterization of a new human hepatocellular carcinoma cell line.

Authors:  L He; K J Isselbacher; J R Wands; H M Goodman; C Shih; A Quaroni
Journal:  In Vitro       Date:  1984-06

8.  Cell-surface changes associated with transformation of human hepatocytes to the malignant phenotype.

Authors:  B Wilson; M Ozturk; H Takahashi; P Motté; M Kew; K J Isselbacher; J R Wands
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

9.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

10.  beta-Hydroxyasparagine in domains homologous to the epidermal growth factor precursor in vitamin K-dependent protein S.

Authors:  J Stenflo; A Lundwall; B Dahlbäck
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

View more
  63 in total

1.  Precision-cut slice culture method for rat placenta.

Authors:  J Gilligan; M Tong; L Longato; S M de la Monte; F Gundogan
Journal:  Placenta       Date:  2011-11-12       Impact factor: 3.481

2.  Ceramide inhibitor myriocin restores insulin/insulin growth factor signaling for liver remodeling in experimental alcohol-related steatohepatitis.

Authors:  Diana Lizarazo; Valerie Zabala; Ming Tong; Lisa Longato; Suzanne M de la Monte
Journal:  J Gastroenterol Hepatol       Date:  2013-10       Impact factor: 4.029

3.  A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma.

Authors:  Arihiro Aihara; Chiung-Kuei Huang; Mark J Olsen; Qiushi Lin; Waihong Chung; Qi Tang; Xiaoqun Dong; Jack R Wands
Journal:  Hepatology       Date:  2014-08-25       Impact factor: 17.425

4.  Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma.

Authors:  Yoshito Tomimaru; Hironori Koga; Hirohisa Yano; Suzanne de la Monte; Jack R Wands; Miran Kim
Journal:  Liver Int       Date:  2013-05-08       Impact factor: 5.828

5.  Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma.

Authors:  Katsuya Nagaoka; Xuewei Bai; Kosuke Ogawa; Xiaoqun Dong; Songhua Zhang; Yanmei Zhou; Rolf I Carlson; Zhi-Gang Jiang; Steve Fuller; Michael S Lebowitz; Hossein Ghanbari; Jack R Wands
Journal:  Cancer Lett       Date:  2019-02-12       Impact factor: 8.679

6.  Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma.

Authors:  Masafumi Shimoda; Yoshito Tomimaru; Kevin P Charpentier; Howard Safran; Rolf I Carlson; Jack Wands
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

7.  Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.

Authors:  Yoshito Tomimaru; Sasmita Mishra; Howard Safran; Kevin P Charpentier; William Martin; Anne S De Groot; Stephen H Gregory; Jack R Wands
Journal:  Vaccine       Date:  2015-01-25       Impact factor: 3.641

8.  Gene-environment interactions of novel variants associated with head and neck cancer.

Authors:  Caihua Liang; Carmen J Marsit; E Andres Houseman; Rondi Butler; Heather H Nelson; Michael D McClean; Karl T Kelsey
Journal:  Head Neck       Date:  2011-11-02       Impact factor: 3.147

9.  Role of aspartyl-(asparaginyl)-β-hydroxylase mediated notch signaling in cerebellar development and function.

Authors:  Elizabeth Silbermann; Peter Moskal; Nathaniel Bowling; Ming Tong; Suzanne M de la Monte
Journal:  Behav Brain Funct       Date:  2010-11-04       Impact factor: 3.759

10.  Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival.

Authors:  C A Barton; B S Gloss; W Qu; A L Statham; N F Hacker; R L Sutherland; S J Clark; P M O'Brien
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.